CN106176770A - A kind of male's period of development injecting narcotic - Google Patents

A kind of male's period of development injecting narcotic Download PDF

Info

Publication number
CN106176770A
CN106176770A CN201610539812.2A CN201610539812A CN106176770A CN 106176770 A CN106176770 A CN 106176770A CN 201610539812 A CN201610539812 A CN 201610539812A CN 106176770 A CN106176770 A CN 106176770A
Authority
CN
China
Prior art keywords
component
male
development
period
injecting narcotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610539812.2A
Other languages
Chinese (zh)
Inventor
孙剑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610539812.2A priority Critical patent/CN106176770A/en
Publication of CN106176770A publication Critical patent/CN106176770A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The present invention relates to a kind of male's period of development injecting narcotic, comprising: component A:

Description

A kind of male's period of development injecting narcotic
Technical field
The present invention relates to a kind of male's period of development injecting narcotic.
Background technology
Anesthetics is requisite medicine in medical surgery, is generally divided into general anesthetic and local anesthetic, and complete Body anesthetics deeply suppresses cerebral cortex, makes people's mind disappear.Tradition use general anesthetic by ether and fluorochemical, But such medicine storage request is higher, and photodissociation, pyrolysis, poor stability easily occur, and deposits and there is impurity the most at once, impact anesthesia effect Really, when using especially for male's period of development, being easily caused auximone disorderly, impact is grown.Therefore in the urgent need to exploitation one Plant the stable anesthetis of safe handling.
Summary of the invention
It is an object of the invention to provide one and deposit stable, free from admixture produces, use safe efficient, have no side effect Male's period of development injecting narcotic.
The technical scheme is that a kind of male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
Described component A:B:C:D:E mass ratio=1.5:0.8:3:18:2.
Use this compound to prepare anesthetics, can avoid producing, store, transport in decompose and produce impurity, to the period of development Male without impact, improve safety in utilization.
Detailed description of the invention
A kind of male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
Described component A:B:C:D:E mass ratio=1.5:0.8:3:18:2.

Claims (2)

1. male's period of development injecting narcotic, comprising:
Component A:；
Component B:2-hydroxy propyl-Beta-ring is stuck with paste；
Component C:[2-(8,9-dioxo-2,6-diazabicyclos [5.2.0] nonyl-1-(7)-alkene-2-base) ethyl] phosphonic acids;
Component D: marcaine;
Component E: etomidate and WS-23 are by quality 2:1 eutectic mixture.
A kind of male's period of development injecting narcotic the most according to claim 1, is characterized in that: described component A:B:C:D:E Mass ratio=1.5:0.8:3:18:2.
CN201610539812.2A 2016-07-11 2016-07-11 A kind of male's period of development injecting narcotic Pending CN106176770A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610539812.2A CN106176770A (en) 2016-07-11 2016-07-11 A kind of male's period of development injecting narcotic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610539812.2A CN106176770A (en) 2016-07-11 2016-07-11 A kind of male's period of development injecting narcotic

Publications (1)

Publication Number Publication Date
CN106176770A true CN106176770A (en) 2016-12-07

Family

ID=57473693

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610539812.2A Pending CN106176770A (en) 2016-07-11 2016-07-11 A kind of male's period of development injecting narcotic

Country Status (1)

Country Link
CN (1) CN106176770A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765582A (en) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 Deuterium-labelled ketamine
CN101896205A (en) * 2007-08-27 2010-11-24 惠氏有限责任公司 Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect
US8128906B2 (en) * 2003-10-08 2012-03-06 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128906B2 (en) * 2003-10-08 2012-03-06 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
CN101765582A (en) * 2007-04-26 2010-06-30 奥斯拜客斯制药有限公司 Deuterium-labelled ketamine
CN101896205A (en) * 2007-08-27 2010-11-24 惠氏有限责任公司 Use nmda antagonist to be used to obtain the compositions and the method for anesthetic-sparing effect

Similar Documents

Publication Publication Date Title
NZ732507A (en) Improved compositions for treating muscular dystrophy
AU2017265011B2 (en) Methods of administering high concentrations of nitric oxide
RU2013156378A (en) 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for use in the treatment of adenocystic carcinoma
MX347544B (en) Polycyclic lpa1 antagonist and uses thereof.
NZ714963A (en) Compositions and methods for treating anemia
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
SG10201805657PA (en) Composite formulation for oral administration comprising ezetimibe and rosuvastatin
MX2022003486A (en) Therapeutic acid ceramidase compositions and methods of making and using them.
NZ630346A (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
CN106176770A (en) A kind of male's period of development injecting narcotic
CN106109468A (en) A kind of women period of development injecting narcotic
MX2015011624A (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles.
RU2015147555A (en) COMPOUNDS MODIFICATING TELOMERS BY TELOMERASE
CN106176762A (en) A kind of local anesthesia anesthetis
MX2021001845A (en) A combination medicament comprising phenylephrine and paracetamol.
CN106166159A (en) A kind of compound injection anesthetis
ZA202200227B (en) Stable oral composition of cyclophosphamide
CN106187850A (en) One can be used as narcotic compound
CN106176746A (en) A kind of child's injecting narcotic
CN106038487A (en) Intravenous injection emulsion anesthetic for pregnant women
Küçük et al. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder: a perspective from anesthesiologists
RU2018114922A (en) TREATMENT OF Focal Alopecia
CN106565580A (en) Anesthetic stabilizer
JOP20190019A1 (en) PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
CN103751178B (en) The application of Trigoxyphin K in increased platelets counts medicine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161207